Hemophilia Products Do Not Raise Antibody Risk, Says EMAHemophilia Products Do Not Raise Antibody Risk, Says EMA

The evidence does not indicate that two recombinant factor VIII products from Bayer increase the risk for inhibitors that render treatment ineffective, EU regulators said in a meta-analysis. News Alerts
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Hematology-Oncology News Alert Source Type: news